Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Inclusion Criteria:

• Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater thanor equal to 16 despite stable treatment with H1 antihistamine consistent withstandard of care

• Must be on a stable dose of H1 antihistamine up to 4 times the approved dose perlocal treatment guidelines

Exclusion Criteria:

• Urticaria with a clear underlying etiology other than CSU

• Urticaria with a clearly defined or sole trigger (chronic inducible urticaria)

• Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis,bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)